免疫原性细胞死亡
免疫系统
免疫疗法
前药
癌症研究
药品
癌症免疫疗法
化学
化疗
鬼臼毒素
药物输送
程序性细胞死亡
聚乙二醇
细胞毒性
获得性免疫系统
细胞毒性T细胞
癌症
药理学
癌细胞
癌症治疗
活性氧
紫杉醇
树突状细胞
毒品携带者
阿霉素
PD-L1
细胞
医学
免疫
T细胞
免疫学
作者
Haitao Zhang,Yining Wang,Lujing Li,Lc Huang,Minghai Huang,Xiaxin Ye,Huilin Zheng,Yun Li,Yang Kang
摘要
Immunotherapy and chemotherapy for tumors still confront significant obstacles, which call for the creation of new potent treatment approaches. One promising strategy to improve anticancer immune responses is to induce immunogenic cell death (ICD) in tumor cells. However, currently available ICD-inducing agents are limited by several factors, including homogeneous mechanisms of action, low induction efficiency, and complex preparation or administration procedures. To improve ICD induction, particularly in immunologically "cold" tumors, this study proposes a drug co-delivery system designed to achieve effective chemotherapy and multi-pathway ICD induction, thereby enhancing antitumor immunity and improving the efficacy of chemoimmunotherapy. Specifically, a poly(podophyllotoxin)-based polymer was engineered to encapsulate the carbon monoxide (CO) prodrug COP, followed by surface modification with D-α-tocopheryl polyethylene glycol succinate, a stabilizing agent that promotes reactive oxygen species (ROS) generation. This design yielded a ROS cascade-amplified drug delivery platform for chemoimmunotherapy. Damage-associated molecular patterns (DAMPs) were released when ROS, CO, and podophyllotoxin combined to trigger ICD in cancer cells. Subsequently, these DAMPs facilitated the activation and maturation of dendritic cells, which then attracted cytotoxic T lymphocytes, thereby amplifying antitumor immune responses and improving treatment results.
科研通智能强力驱动
Strongly Powered by AbleSci AI